• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ex pharma execs first to be charged in generic drug pricing case

December 15, 2016 By Sarah Faulkner

Ex pharma execs first to be charged in generic drug pricing caseFormer Heritage Pharmaceuticals CEO Jeffrey Glazer and ex-president Jason Malek were hit yesterday with the 1st criminal charges from a 2-year federal investigation in an ongoing generic drug pricing case. The 2 former executives were charged by federal authorities with price collusion for doxycycline hyclate, a widely used antibiotic, and a diabetes therapy called glyburide from 2013 and 2015.

Other drug makers have reportedly received subpoenas as a part of the U.S. Justice Dept. probe. Bloomberg News reported that Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA), and Endo International’s Par subsidiary are among the companies being investigated by federal authorities for co-conspirating to fix the market for generic drugs.

Pharmaceutical companies have been under fire this year for their pricing strategies. Mylan has endured criticism for months following reports that it jacked the price of its EpiPen by 500% since acquiring the epinephrine auto-injector from Merck (NYSE:MRK) in 2007. In early October, the company agreed to pay $465 million to settle claims that it underpaid Medicaid for its EpiPen auto-injector by misclassifying the device as a generic.

Heritage filed a racketeering lawsuit against Glazer and Malek last November, accusing the pair of a “long-running criminal conspiracy that severely damaged Heritage.” The Eatontown, N.J.-based company alleged that the 2 executives redirected millions of dollars of Heritage sales to dummy corporations like Dorado Pharma from 2012 to 2015. The 2 were fired in August this year.

According to court documents, “Glazer and Malek looted tens of millions of dollars from Heritage by misappropriating its business opportunities, fraudulently obtaining compensation for themselves, and embezzling its intellectual property.”

The company is cooperating with the U.S. Justice Dept. investigation and is “deeply disappointed by the misconduct and are committed to ensuring it does not happen again,” a spokeswoman told Stat News.

Filed Under: Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Heritage Pharmaceuticals, Mylan, Teva Pharmaceuticals, U.S. Justice Dept.

IN CASE YOU MISSED IT

  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Senseonics beats The Street in Q1 following Eversense E3 launch

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS